Midazolam "hameln" (Midazolam Hydrochloride)

Midazolam binds to a specific site on the GABA‑A receptor, enhancing the inhibitory effect of the neurotransmitter GABA. This increases chloride ion flow into neurons, hyperpolarizing them and reducing neuronal excitability, which produces sedation, anxiolysis, anticonvulsant activity, and muscle relaxation.

The dose of Midazolam "hameln" is determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and route of administration. Healthcare professionals tailor the dosage to achieve the desired sedative or anticonvulsant effect while minimizing adverse reactions.

Midazolam is classified as a pregnancy category that requires careful risk‑benefit assessment. It should only be used if the potential therapeutic benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare provider, as the drug can be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Midazolam offers a rapid onset of action and a short duration of effect compared with many other benzodiazepines, making it suitable for procedural sedation and seizure control. Its potency and ability to be administered via multiple routes (IV, IM, rectal) provide flexibility not always available with alternatives such as diazepam or lorazepam.

Midazolam "hameln" should be stored at controlled room temperature, typically below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain its stability and sterility.

Midazolam "hameln" is supplied as a sterile injectable solution and can be administered intravenously, intramuscularly, or rectally, depending on the clinical indication. The route and rate of administration are determined by the treating physician to achieve the desired therapeutic effect.

The most serious risks include profound respiratory depression, severe hypotension, paradoxical reactions such as agitation or aggression, and rare cases of anaphylaxis. Continuous monitoring of respiratory and cardiovascular status is essential, especially when used with other central nervous system depressants.

Midazolam "hameln" is contraindicated in patients with known hypersensitivity to benzodiazepines, severe respiratory insufficiency, acute narrow‑angle glaucoma, or those who have taken large amounts of alcohol or other CNS depressants. Caution is also advised for individuals with myasthenia gravis or severe hepatic impairment.